Stay updated with breaking news from Biliary Tract. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy aloneWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tra...
Dublin, June 28, 2022 (GLOBE NEWSWIRE) -- The "Biliary Tract Cancers (BTCs) - Market Insight, Epidemiology And Market Forecast - 2032" report has been...
The agency has updated its April 2020 guidance after postmarket surveillance found partially or fully disposable models can cut the risk of between-patient contamination by 50% or more.
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...
TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients...